Blog Posts

OncoDaily

News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

August, 2025

Blog Posts

Patients with loss of Y chromosome (LOY) had poorer prognosis when their bladders were removed, but somewhat paradoxically, better overall survival rates when they received immune checkpoint inhibitors

Photo from cedars-sinai.org

Jun 26, 2023, 19:13

Patients with loss of Y chromosome (LOY) had poorer prognosis when their bladders were removed, but somewhat paradoxically, better overall survival rates when they received immune checkpoint inhibitors

In a post by on Linkedin, it says, “It is terrific to see our study examining the loss of Y chromosome (LOY) and its effect on bladder cancer has been published in Nature. The loss of the Y chromosome has been observed in several cancer types, including many bladder cancers. The paper describes our studies of naturally occurring LOY mutant bladder cancer cells as well as those with targeted deletion of Y chromosome by CRISPR/Cas9. We found Y- tumors were more aggressive in immune competent hosts in a T cell-dependent manner. Our study also reviewed data on male patients with invasive bladder cancer who had their bladders removed and male patients who participated in an immune checkpoint inhibitor clinical trial. Patients with LOY had poorer prognosis when their bladders were removed, but somewhat paradoxically, better overall survival rates when they received immune checkpoint inhibitors.
These findings could also have implications for women since they experience more aggressive bladder cancer. The Y chromosome possesses a set of related genes, called paralogue genes, on the X chromosome, and these might play a role in both women and men.
We believe this study is the first published evidence that LOY cancer alters T cell function, allowing bladder cancer to elude the immune system and grow more aggressively. It provides insights into LOY biology and lays the groundwork for developing future biomarkers to improve cancer immunotherapy. I’d like to thank all of my fellow authors and everyone who helped with this research.”

For details: Click here

Source:

bladder cancer cancer clinical trial Dan Theodorescu immunotherapy OncoDaily Oncology paralogue genes T cell-dependent X chromosome Y chromosome

'

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...

'

World’s Nicest Judge Frank Caprio Dies at 88 After Brave Battle with Pancreatic Cancer

'

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

'

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

'

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023

Insight

Aug 21, 2025, 15:37

Carolina Reduzzi: ctDNA Landscape Analysis Post CDK4/6 Inhibitor in HR+/HER2- Metastatic Breast Cancer

Voices

Aug 21, 2025, 15:30

Clinician-Scientists Awarded NMRC Transition Awards for Precision Lung Cancer Research - National Cancer Centre Singapore

Voices

Aug 21, 2025, 15:22

Construction of the $658 million Sydney Children’s Hospital Stage One and MCCCC Project Has Reached Completion

Oncolibrary

Aug 21, 2025, 15:00

Breakthrough Emactuzumab Phase 3 TANGENT Trial in TGCT: SynOx Pharma Reports Enrollment Completed Ahead of Schedule

Voices

Aug 21, 2025, 14:50

Andrea Apolo Highlights the Top 5 Clinical Advances in Bladder Cancer Treatment for 2024

Insight

Aug 21, 2025, 14:47

Loay Kassem: Study Reveals BRCA Mutation Rates in Egyptian Women with Breast or Ovarian Cancer

Insight

Aug 21, 2025, 14:41

Tiago Cordeiro Felismino: Exploring the Role of Neutrophil-to-Lymphocyte Ratio in Advanced HCC Treatment

Voices

Aug 21, 2025, 14:40

Larissa Nekhlyudov Celebrates Leadership of Emily Smith Tonorezos and Michelle Mollica in Cancer Survivorship

Voices

Aug 21, 2025, 14:32

Hayley Jones: McCabe Centre Supports Daffodil Day with 38,000 Daffodils for Cancer Awareness

Voices

Aug 21, 2025, 14:26

Chrystal Paulos: Exciting Opportunities to Build with the Paulos Lab at Winship Cancer Institute

Voices

Aug 21, 2025, 14:21

Caryn Lerman: HPV16 Causes More Than Half of Cervical Cancer Cases

Voices

Aug 21, 2025, 14:18

Svetlana Nikic: Changing the Game in Precision Oncology Education